{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:09:00Z","timestamp":1785802140604,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04489-x","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:34:56Z","timestamp":1754044496000},"page":"1197-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD"],"prefix":"10.1007","volume":"399","author":[{"given":"Gustavo Adolfo","family":"V\u00e1squez-Tirado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edinson Dante","family":"Meregildo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Vanessa","family":"Quispe-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson Marcial","family":"Guzm\u00e1n-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Jacqueline","family":"Li\u00f1\u00e1n-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy Hern\u00e1n","family":"Abanto-Montalv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Serna-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Alva-Guarniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Ortiz-Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis \u00c1ngel","family":"Rodr\u00edguez-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Cuadra-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"3","key":"4489_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","volume":"5","author":"H Abdel-Qadir","year":"2023","unstructured":"Abdel-Qadir H, Carrasco R, Austin PC et al (2023) The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol 5(3):318\u2013328. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.011","journal-title":"JACC CardioOncol"},{"key":"4489_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjcard.2024.01.032","volume":"216","author":"S Agarwal","year":"2024","unstructured":"Agarwal S, Qamar U, Fujiwara Y et al (2024) The effect of Sodium-Glucose Cotransporter-2 inhibitors on cardiovascular outcomes in patients with cancer: a systematic review and meta-analysis. Am J Cardiol 216:87\u201390. https:\/\/doi.org\/10.1016\/j.amjcard.2024.01.032","journal-title":"Am J Cardiol"},{"issue":"1","key":"4489_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula V, Sharma G, Kosiborod MN et al (2024) SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC: Heart Failure 12(1):67\u201378. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.026","journal-title":"JACC: Heart Failure"},{"key":"4489_CR4","doi-asserted-by":"publisher","unstructured":"Bashai C, Kazma N, Haiim I, et al (2021) Cardio-oncology in a dish: Cardiovascular tissue engineering strategies for modeling cancer therapy related cardiac dysfunction. Circ 144(SUPPL 1). https:\/\/doi.org\/10.1161\/circ.144.suppl_1.13887","DOI":"10.1161\/circ.144.suppl_1.13887"},{"issue":"10","key":"4489_CR5","doi-asserted-by":"publisher","first-page":"e72313","DOI":"10.7759\/cureus.72313","volume":"16","author":"J Benko","year":"2024","unstructured":"Benko J, P\u00e9\u010d MJ, Tom\u010dov\u00e1 Z, P\u00e9\u010dov\u00e1 M, Samo\u0161 M (2024) Cardiotoxicity of BRAF\/MEK inhibitors mimicking apical hypertrophic cardiomyopathy. Cureus 16(10):e72313. https:\/\/doi.org\/10.7759\/cureus.72313","journal-title":"Cureus"},{"key":"4489_CR6","doi-asserted-by":"publisher","unstructured":"Bhalraam U, Veerni RB, Paddock S, et al (2025) Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prevent Cardiol. Published online March 6, 2025:zwaf026. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026","DOI":"10.1093\/eurjpc\/zwaf026"},{"issue":"6","key":"4489_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS et al (2024) SGLT2i and primary prevention of cancer therapy\u2013related cardiac dysfunction in patients with diabetes. JACC: CardioOncology 6(6):863\u2013875. https:\/\/doi.org\/10.1016\/j.jaccao.2024.08.001","journal-title":"JACC: CardioOncology"},{"issue":"5","key":"4489_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity in adult cancer patients. JACC: CardioOncology 6(5):655\u2013677. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016","journal-title":"JACC: CardioOncology"},{"issue":"6","key":"4489_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","volume":"109","author":"CH Chiang","year":"2023","unstructured":"Chiang CH, Chiang CH, Chiang CH et al (2023) Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart 109(6):470\u2013477. https:\/\/doi.org\/10.1136\/heartjnl-2022-321545","journal-title":"Heart"},{"key":"4489_CR10","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Accessed December 27, 2023. https:\/\/training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"6","key":"4489_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jaccao.2024.10.005","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, Blaes AH, Ramu B, Zordoky BNA (2024) SGLT2 inhibitors in mitigating cancer therapy-related cardiac dysfunction: expanding the evidence. JACC: CardioOncology 6(6):876\u2013878. https:\/\/doi.org\/10.1016\/j.jaccao.2024.10.005","journal-title":"JACC: CardioOncology"},{"key":"4489_CR12","doi-asserted-by":"publisher","unstructured":"Daniele AJ, Gregorietti V, Costa D, L\u00f3pez \u2013 Fern\u00e1ndez T (2024) Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD \u2013 PILOT trial. Cardio-Oncol 10(1). https:\/\/doi.org\/10.1186\/s40959-024-00260-y","DOI":"10.1186\/s40959-024-00260-y"},{"key":"4489_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.amjcard.2024.04.032","volume":"222","author":"AR Fath","year":"2024","unstructured":"Fath AR, Aglan M, Aglan A et al (2024) Cardioprotective potential of Sodium-glucose cotransporter-2 inhibitors in patients with cancer treated with anthracyclines: an observational study. Am J Cardiol 222:175\u2013182. https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.032","journal-title":"Am J Cardiol"},{"key":"4489_CR14","doi-asserted-by":"publisher","unstructured":"Gongora CA, Zhang L, Mattei JL, et al (2024) Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care? Cardiovasc Drugs Ther. ((Gongora C.A.; Zhang L.; Slipczuk L.) Division of Cardiology, Montefiore Medical Center at Albert Einstein School of Medicine, Bronx, NY, United States). https:\/\/doi.org\/10.1007\/s10557-024-07604-x","DOI":"10.1007\/s10557-024-07604-x"},{"issue":"5","key":"4489_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","volume":"123","author":"A Granholm","year":"2019","unstructured":"Granholm A, Alhazzani W, M\u00f8ller MH (2019) Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth 123(5):554\u2013559. https:\/\/doi.org\/10.1016\/j.bja.2019.08.015","journal-title":"Br J Anaesth"},{"key":"4489_CR16","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Chapter 4 Pooling Effect Sizes | Doing Meta-Analysis in R. Accessed June 11, 2024. https:\/\/bookdown.org\/MathiasHarrer\/ng_Meta_Analysis_in_R\/pooling-es.html"},{"key":"4489_CR17","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Chapter 9 Publication Bias | Doing Meta-Analysis in R. Accessed June 11, 2024. https:\/\/bookdown.org\/MathiasHarrer\/ng_Meta_Analysis_in_R\/pub-bias.html"},{"issue":"1","key":"4489_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"4489_CR19","doi-asserted-by":"publisher","first-page":"21756","DOI":"10.1038\/s41598-023-48678-1","volume":"13","author":"HJ Hwang","year":"2023","unstructured":"Hwang HJ, Kim M, Jun JE, Yon DK (2023) Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea. Sci Rep 13(1):21756. https:\/\/doi.org\/10.1038\/s41598-023-48678-1","journal-title":"Sci Rep"},{"issue":"1","key":"4489_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13098-024-01354-4","volume":"16","author":"HH Kuo","year":"2024","unstructured":"Kuo HH, Wang KT, Chen HH et al (2024) Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis. Diabetol Metab Syndr 16(1):108. https:\/\/doi.org\/10.1186\/s13098-024-01354-4","journal-title":"Diabetol Metab Syndr"},{"key":"4489_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104577","volume":"151","author":"X Li","year":"2020","unstructured":"Li X, Li Y, Zhang T et al (2020) Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res 151:104577. https:\/\/doi.org\/10.1016\/j.phrs.2019.104577","journal-title":"Pharmacol Res"},{"issue":"3","key":"4489_CR22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H (2018) Quantifying publication bias in meta-analysis. Biometrics 74(3):785\u2013794. https:\/\/doi.org\/10.1111\/biom.12817","journal-title":"Biometrics"},{"key":"4489_CR23","unstructured":"L\u00f3pez-Fernandez\u2019 \u2019Teresa, Dent\u2019 \u2019Susan Faye (2025) Strategies for risk stratification and cardiovascular toxicity prevention in patients with cancer. Accessed March 16, 2025. https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/strategies-for-risk-stratification-and-cardiovascular-toxicity-prevention-in-pat"},{"issue":"41","key":"4489_CR24","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"4489_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","volume":"3","author":"N Meader","year":"2014","unstructured":"Meader N, King K, Llewellyn A et al (2014) A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev 3:82. https:\/\/doi.org\/10.1186\/2046-4053-3-82","journal-title":"Syst Rev"},{"key":"4489_CR26","doi-asserted-by":"publisher","unstructured":"Meregildo-Rodriguez ED, Asmat-Rubio MG, V\u00e1squez-Tirado GA (2023) SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis. Front Endocrinol 14. https:\/\/doi.org\/10.3389\/fendo.2023.1307715","DOI":"10.3389\/fendo.2023.1307715"},{"issue":"10","key":"4489_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s11912-024-01577-8","volume":"26","author":"N Osataphan","year":"2024","unstructured":"Osataphan N, Abdel-Qadir H, Zebrowska AM, Borowiec A (2024) Sodium-glucose cotransporter 2 inhibitors during cancer therapy: benefits, risks, and ongoing clinical trials. Curr Oncol Rep 26(10):1188\u20131196. https:\/\/doi.org\/10.1007\/s11912-024-01577-8","journal-title":"Curr Oncol Rep"},{"key":"4489_CR28","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"issue":"23","key":"4489_CR29","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K et al (2024) Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation 149(23):1789\u20131801. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069568","journal-title":"Circulation"},{"issue":"1","key":"4489_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40959-023-00199-6","volume":"10","author":"MG Perelman","year":"2024","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B et al (2024) Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology 10(1):2. https:\/\/doi.org\/10.1186\/s40959-023-00199-6","journal-title":"Cardiooncology"},{"key":"4489_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1289663","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Canale M, Bisceglia I et al (2024) Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2024.1289663","journal-title":"Front Cardiovasc Med"},{"key":"4489_CR32","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"4489_CR33","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"3","key":"4489_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA: A Cancer J Clin"},{"issue":"1","key":"4489_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C (2017) Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 17(1):39. https:\/\/doi.org\/10.1186\/s12874-017-0315-7","journal-title":"BMC Med Res Methodol"},{"key":"4489_CR36","doi-asserted-by":"publisher","unstructured":"Yan Z, Xing X, Huang J (2025) The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis. Biomol Biomed. Published online March 10, 2025. https:\/\/doi.org\/10.17305\/bb.2025.11847","DOI":"10.17305\/bb.2025.11847"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04489-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:03:02Z","timestamp":1771538582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04489-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4489"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04489-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}